|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B: Liver fibrosis and hepatocellular carcinoma显示文摘 | A.S.F. Lok | 2009 | Gastroenterologie Clinique et Biologique2009，，10： | 2 |
| 2 | The cost of cerebral ischaemia显示文摘 | R.W.V. Flynn R.S.M. MacWalter A.S.F. Doney | 2008 | Neuropharmacology2008，，3： | 1 |
| 3 | 标准实验室检查预测丙型肝炎患者肝硬化:HALT-C队列研究结果 | Lok A.S.F. Ghany M.G. Goodman Z.D. 徐瑞 | 2005 | 世界核心医学期刊文摘(胃肠病学分册)2005，0，11： | 1 |
| 4 | Mechanisms of bee venom-induced acute renal failure显示文摘 | Luciana S.D. Grisotto Glória E. Mendes Isac Castro Maria A.S.F. Baptista Venancio A. Alves Luis Yu Emmanuel A. Burdmann | 2006 | Toxicon2006，，1： | 1 |
| 5 | 阿德福韦耐药的乙型肝炎与病毒反跳和肝脏失代偿有关显示文摘Background/Aims: The susceptibility of adefovir-resistant hepatitis B virus ( HBV) mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely. The aim of this study was to describe the clinical course of patients with adefovir-resistant HBV infection. Methods: Testing for adefovir-resistant mutations was performed on patients who had a suboptimal response or virologic breakthrough on adefovir. Adefovir-resistant mutations were detected using a line probe assay and direct sequencing of the HBV P-gene. Results: Eight male patients with pre-existing lamivudine resistance or breakthrough (mean age 47±13 years) were found to have adefovir-resistant mutations rtA181V/T or rtN236T. Baseline median ALT was 66 IU/L (range, 27-1161) and median HBV DNA 7.9 log10 copies/ml (range, 6-8.3). A t the time of adefovir resistance (mean of 20±9 months), HBV DNA increased to ≥5 log10 copies/ml in 7 patients. After detection of adefovir resistance, hepat ic decompensation occurred in 2 patients, 1 of whom died. Salvage therapy with l amivudine, entecavir or tenofovir was given to 7 patients and a reduction in HBV DNA by ≥3 log10 was seen in 3 patients. Conclusions: In conclusion, adefovir r esistance can be associated with significant viral rebound and hepatic decompens ation which may be fatal. | Fung S.K Andreone P Han S.H. A.S.F. Lok 孟欣颖 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，0，4： | 0 |
| 6 | 慢性乙型肝炎患者对阿德福韦的病毒学应答和耐药性研究显示文摘Abstract Abstract Background: The incidence and risk factors for adefovir-resistant HBV have not been clearly defined. Aims: To characterize the virologic response to adefovir, to determine the rate of adefovir resistance and to explore factors associated with initial virologic response (IVR) and adefovir resistance. Methods: All hepatitis B patients who received adefovir for ≥ 6 months at our center were prospectively monitored for virologic response and adefovir resistance. Results: Forty three patients were included; mean treatment duration was 18 months (range 6-45). Thirty four (79% ) patients had prior lamivudine. IVR was observed in 44% patients and associated with higher pretreatment ALT (P=0.05) and the absence of HBeAg (P=0.02). Six (14% ) patients were found to have adefovir-resistant mutations. The cumulative probability of genotypic resistance to adefovir at month 24 was 22% . Patients with adefovir resistance were more likely to have been switched from lamivudine to adefovir monotherapy (P=0.01), to be older (P=0.04), and to be infected with HBV genotype D (P=0.02). Conclusions: Roughly 50% of patients failed to achieve IVR on adefovir. The cumulative probability of adefovir resistance at 2 years was 22% . Our data suggest that combination of lamivudine and adefovir may prevent emergence of adefovir resistance in patients with lamivudine-resistant HBV. | Fung S.K. Chae H.B. Fontana R.J. A.S.F. Lok 刘丽娜 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员